PharmaEssentia

6446.TW

16.65 USD

0.50

+3.10%

Overview

Last close

16.65 usd

Market cap

5.68B usd

52 week high

23.57 usd

52 week low

8.76 usd

Target price

22.5 usd

Valuation

P/E

42.1617

Forward P/E

N/A

Price/Sales

13.4787

Price/Book Value

5.7732

Enterprise Value

4.72B usd

EV/Revenue

11.4716

EV/EBITDA

39.1959

Key financials

Revenue TTM

411.69M usd

Gross Profit TTM

362.93M usd

EBITDA TTM

117.12M usd

Earnings per Share

0.39 usd

Dividend

0.04 usd

Total assets

867.04M usd

Net debt

-583.77M usd

About

PharmaEssentia Corporation, a biopharmaceutical company engages in treatment for human diseases in Taiwan and internationally. Its products include Ropeginterferon alfa-2b that is used for the treatment of chronic myelogenous leukemia, T-Cell leukemia, early myelofibrosis, polycythemia vera, and essential thrombocythemia. The company also develops TCRT, anti PD-1, PEG-cytokine X,Y, and novel checkpoint abs for the treatment of solid tumors; P1101 + anti PD-1 for the treatment of hepatocellular carcinoma; and PEG-GCSF for the treatment of neutropenia. In addition, it focuses on the drug research and development programs in the areas of hematology, infectious disease, and oncology. PharmaEssentia Corporation was founded in 1990 and is headquartered in Taipei, Taiwan.